Top Markets
#1 Akedo Akedo +179.90%
#2 TENDIES TENDIES +90.81%
#3 Threshold Network Threshold Network +48.52%
#4 Verus Coin Verus Coin +43.84%
#5 Mubarak Mubarak +28.98%
#6 Bitway Bitway +28.51%
#7 MultiversX MultiversX +25.94%
#8 Cash Cat Cash Cat +23.23%
#9 Palladium Network Palladium Network +22.69%
#10 aelf aelf +19.29%
Coin of the day
Akedo Akedo
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Shukra Pharmaceuticals Limited Shukra Pharmaceuticals Limited

Shukra Pharmaceuticals Limited

SHUKRAPHAR
Rangering i aksjer #17792
Shukra Pharmaceuticals Limited is a prominent company engaged in the... Shukra Pharmaceuticals Limited is a prominent company engaged in the manufacturing and global distribution of pharmaceutical products. Their comprehensive product line addresses a broad spectrum of medical conditions, encompassing anti-infective medications (such as antibiotics, macrolides, quinolones, antivirals, antifungals, antimalarials, antiprotozoals, and anti-helminthics), central nervous system drugs (including sedatives, tranquilizers, antidepressants, and anti-manic agents), gastrointestinal treatments (like anti-emetics and anti-ulcer drugs), cardiovascular remedies (beta-blockers, diuretics), pain and inflammation management (analgesics, muscle relaxants, corticosteroids), anti-tuberculosis drugs, vitamin supplements, anti-allergy medications, and therapies for metabolic imbalances such as hyper- and hypoglycemia. The company was established on March 4, 1993, and its primary operations are directed from its headquarters in Ahmedabad, India.
Aksjekurs
$0.51647906
Markedsverdi
$226.16M
Endring (1 dag)
5.29%
Endring (1 år)
66.66%
Land
IN
Handel Shukra Pharmaceuticals Limited (SHUKRAPHAR)

Kategori

Healthcare
P/E-forhold for Shukra Pharmaceuticals Limited (SHUKRAPHAR)
P/E-forhold per 2026 TTM: 0
Ifølge Shukra Pharmaceuticals Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Shukra Pharmaceuticals Limited fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 25.48 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
 34.09 -
HK
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.